Angiogenesis inhibitors for the treatment of ovarian cancer

Kezia Gaitskell; Igor Martinek; Andrew Bryant; Sean Kehoe; Shibani Nicum; Jo Morrison

doi:10.1002/14651858.CD007930.pub2

Angiogenesis inhibitors for the treatment of ovarian cancer

Kezia Gaitskell, Igor Martinek, Andrew Bryant, Sean Kehoe, Shibani Nicum, Jo Morrison

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Many women with ovarian cancer eventually develop resistance to conventional chemotherapy drugs, and so novel agents are being developed to target specific molecular pathways. One such class of drugs inhibits angiogenesis (the development of new blood vessels), which is essential for tumour growth. It is important to establish whether the addition of these new drugs to conventional chemotherapy regimens improves survival, and what the side-effects may be.

Original language	English
Pages (from-to)	CD007930
Journal	Cochrane Database of Systematic Reviews
Issue number	9
DOIs	https://doi.org/10.1002/14651858.CD007930.pub2
Publication status	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/14651858.CD007930.pub2

Cite this

@article{2ddb5863a73d442ca160e22a39b303f1,

title = "Angiogenesis inhibitors for the treatment of ovarian cancer",

abstract = "Many women with ovarian cancer eventually develop resistance to conventional chemotherapy drugs, and so novel agents are being developed to target specific molecular pathways. One such class of drugs inhibits angiogenesis (the development of new blood vessels), which is essential for tumour growth. It is important to establish whether the addition of these new drugs to conventional chemotherapy regimens improves survival, and what the side-effects may be.",

author = "Kezia Gaitskell and Igor Martinek and Andrew Bryant and Sean Kehoe and Shibani Nicum and Jo Morrison",

year = "2011",

doi = "10.1002/14651858.CD007930.pub2",

language = "English",

pages = "CD007930",

journal = "Cochrane Database of Systematic Reviews",

issn = "1469-493X",

publisher = "Cochrane Collaboration",

number = "9",

}

TY - JOUR

T1 - Angiogenesis inhibitors for the treatment of ovarian cancer

AU - Gaitskell, Kezia

AU - Martinek, Igor

AU - Bryant, Andrew

AU - Kehoe, Sean

AU - Nicum, Shibani

AU - Morrison, Jo

PY - 2011

Y1 - 2011

N2 - Many women with ovarian cancer eventually develop resistance to conventional chemotherapy drugs, and so novel agents are being developed to target specific molecular pathways. One such class of drugs inhibits angiogenesis (the development of new blood vessels), which is essential for tumour growth. It is important to establish whether the addition of these new drugs to conventional chemotherapy regimens improves survival, and what the side-effects may be.

AB - Many women with ovarian cancer eventually develop resistance to conventional chemotherapy drugs, and so novel agents are being developed to target specific molecular pathways. One such class of drugs inhibits angiogenesis (the development of new blood vessels), which is essential for tumour growth. It is important to establish whether the addition of these new drugs to conventional chemotherapy regimens improves survival, and what the side-effects may be.

U2 - 10.1002/14651858.CD007930.pub2

DO - 10.1002/14651858.CD007930.pub2

M3 - Article

C2 - 21901715

SN - 1469-493X

SP - CD007930

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 9

ER -

Angiogenesis inhibitors for the treatment of ovarian cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this